(Q82892839)
Statements
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer (English)
Tanja Cufer
Eduard Vrdoljak
Rabab Gaafar
Inci Erensoy
Kristine Pemberton
SIGN Study Group